These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. DOSAGES OF VARIOUS TRIVALENT AND MONOVALENT ADENOVIRUS VACCINES IN THE PROPHLAXIS OF ACUTE RESPIRATORY ILLNESS. STILLE WT, HANTOVER MJ. Am J Hyg; 1964 Jul; 80():121-34. PubMed ID: 14192764 [No Abstract] [Full Text] [Related]
24. Acute respiratory infections in civilian adults. I. Antibody response to polyvalent influenza--adenovirus inactivated vaccine. COX F, TIMM EA, QUINN EL, COLVILLE JM, McLEAN IW. Henry Ford Hosp Med Bull; 1962 Mar; 10():27-33. PubMed ID: 13881896 [No Abstract] [Full Text] [Related]
25. TESTING THE EFFECTIVENESS OF LIVE ADENOVIRUS VACCINE. I. REACTOGENIC PROPERTIES. SELIVANOV AA, PLESHANOVA RA, SKRYABINA EA, SMORODINTSEV AA. Acta Virol; 1964 May; 8():263-70. PubMed ID: 14173474 [No Abstract] [Full Text] [Related]
26. Dramatic decline of respiratory illness among US military recruits after the renewed use of adenovirus vaccines. Radin JM, Hawksworth AW, Blair PJ, Faix DJ, Raman R, Russell KL, Gray GC. Clin Infect Dis; 2014 Oct; 59(7):962-8. PubMed ID: 24991024 [Abstract] [Full Text] [Related]
28. TESTING THE EFFECTIVENESS OF LIVE ADENOVIRUS VACCINE. II. IMMUNOGENIC PROPERTIES. SELIVANOV AA, PLESHANOVA RA, SMORODINTSEV AA. Acta Virol; 1964 May; 8():271-6. PubMed ID: 14173475 [No Abstract] [Full Text] [Related]
29. Association of type 21 adenovirus with acute respiratory illness in military recruits. VAN DER VEEN J, DIJKMAN JH. Am J Hyg; 1962 Sep; 76():149-59. PubMed ID: 13925163 [No Abstract] [Full Text] [Related]
30. Second field evaluation of bivalent Types 4 and 7 adenovirus vaccine. HILLEMAN MR, GREENBERG JH, WARFIELD MS, ANDERSON SA, GLABERE RR. AMA Arch Intern Med; 1958 Sep; 102(3):428-36. PubMed ID: 13570730 [No Abstract] [Full Text] [Related]
31. Permissive growth of human adenovirus type 4 vaccine strain-based vector in porcine cell lines. Gao DS, Li XJ, Wan WY, Li HJ, Wang XX, Yang X, Li YT, Chang HT, Chen L, Wang CQ, Zhao J. Res Vet Sci; 2016 Feb; 104():83-5. PubMed ID: 26850542 [Abstract] [Full Text] [Related]
32. Current use and future directions of adenovirus vaccine. Gurwith MJ, Horwith GS, Impellizzeri CA, Davis AR, Lubeck MD, Hung PP. Semin Respir Infect; 1989 Dec; 4(4):299-303. PubMed ID: 2560582 [Abstract] [Full Text] [Related]
33. Enhanced Adenovirus Vaccine Safety Surveillance in Military Setting, United States. Iskander J, Blanchet S, Springer C, Rockwell P, Thomas D, Pillai S. Emerg Infect Dis; 2023 Jun; 29(6):1283-1285. PubMed ID: 37209695 [Abstract] [Full Text] [Related]
34. ADENOVIRUS VACCINE STUDIES. MR 005.09-1203.1. ROSENBAUM MJ, MILLER LF, EDWARDS EA, PIERCE WE. Rep U S Nav Med Res Lab; 1964 Aug 31; 10():1-18. PubMed ID: 24547284 [No Abstract] [Full Text] [Related]
35. [Adenovirus infections in Dutch army recruits]. BEUNDERS B. Arch Gesamte Virusforsch; 1963 Aug 31; 13():302-9. PubMed ID: 13967881 [No Abstract] [Full Text] [Related]
36. Adenovirus infections in Chinese Army recruits on Taiwan. TAI FH, GRAYSTON JT, JOHNSTON PB, WOOLRIDGE RL. J Infect Dis; 1960 Aug 31; 107():160-4. PubMed ID: 13774824 [No Abstract] [Full Text] [Related]
37. Adenovirus 4/7 Vaccine's Effect on Disease Rates Is Associated With Disappearance of Adenovirus on Building Surfaces at a Military Recruit Base. Broderick M, Myers C, Balansay M, Vo S, Osuna A, Russell K. Mil Med; 2017 Nov 31; 182(11):e2069-e2072. PubMed ID: 29087884 [Abstract] [Full Text] [Related]